Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Apixaban (BMS-562247-01) 是一种高度选择性,可逆的、口服具有活力的凝血因子 Xa (Factor Xa) 抑制剂,抑制人和兔凝血因子 Xa 的 Ki 分别为 0.08 nM 和 0.17 nM。它可以用于研究各种血栓栓塞疾病。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 278 | 现货 | ||
2 mg | ¥ 396 | 现货 | ||
5 mg | ¥ 571 | 现货 | ||
10 mg | ¥ 851 | 现货 | ||
50 mg | ¥ 1,280 | 现货 | ||
100 mg | ¥ 1,950 | 现货 | ||
200 mg | ¥ 2,930 | 现货 | ||
500 mg | ¥ 4,130 | 现货 | ||
1 g | ¥ 6,150 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 678 | 现货 |
产品描述 | Apixaban (BMS-562247-01) is an orally active inhibitor of coagulation factor Xa with anticoagulant activity. Apixaban directly inhibits factor Xa, thereby interfering with the conversion of prothrombin to thrombin and preventing the formation of cross-linked fibrin clots. |
靶点活性 | FXa (rabbit):0.17 nM(Ki), FXa (human):0.08 nM(Ki) |
体外活性 | Apixaban在犬体内具有优良的药代动力学特性:极低间隙(Cl: 0.02 L/kg/h),低体积分布 (Vdss: 0.2 L/kg),半衰期(T1/2: 5.8 h)和口服生物有效性(F: 58%).作用于静脉血栓形成、动静脉分流血栓形成和电介导颈动脉血栓兔子模型,Apixaban能够抗血栓形成,EC50分别为110 nM,270 nM和70 nM. |
体内活性 | 作用于体外正常人血浆时,Apixaban延长人凝血时间,使凝血酶原时间(3.6 μM)、改良凝血酶原时间(0.37 μM)、活化部分凝血活酶时间(7.4 μM)和HepTest(0.4 μM)延长一倍。Apixaban对人Factor Xa 和兔Factor Xa的抑制具有高选择,Ki分别为0.08和0.17 nM。此外,在PT和APTT实验中,Apixaban对人和兔血浆的效用最高,对大鼠和犬血浆的效果则较低。 |
激酶实验 | Purified FXa is obtained after activation with Russell's viper venom followed by affinity chromatography. The resulting FXa is > 95% pure as judged by sodium dodecylsulfate polyacrylamide gel electrophoresis. The substrate affinity values for FXa, expressed as the Michaelis-Menten-Henri constant (Km), for human, rabbit, rat and dog FXa are determined using the chromogenic substrate S-2765, and are 36, 60, 240 and 70 μM, respectively. The substrate hydrolysis is monitored by measuring absorbance at 405 nm at 25°C for up to 30 min using a SpectraMax 384 Plus plate reader and SoftMax. FXa activity for each substrate and inhibitor concentration pair is determined in duplicate. The Ki values are calculated by non-linear least-squares fitting of the steady-state substrate hydrolysis rates to the equation for competitive inhibition (Equation 1) using GRAFIT, where v equals reactions velocity in OD min?1, Vmax equals maxiumum reaction velocity, S equals substrate concentration, and I equals inhibitor concentration. |
别名 | 阿哌沙班, BMS-562247-01 |
分子量 | 459.5 |
分子式 | C25H25N5O4 |
CAS No. | 503612-47-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 15 mg/mL (32.6 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.1763 mL | 10.8814 mL | 21.7628 mL | 54.407 mL |
5 mM | 0.4353 mL | 2.1763 mL | 4.3526 mL | 10.8814 mL | |
10 mM | 0.2176 mL | 1.0881 mL | 2.1763 mL | 5.4407 mL | |
20 mM | 0.1088 mL | 0.5441 mL | 1.0881 mL | 2.7203 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Apixaban 503612-47-3 Metabolism Factor Xa 阿哌沙班 Fxa Inhibitor rabbit clotting Factor plasma BMS-562247-01 human EC2x inhibit inhibitor